Day: October 11, 2022

Ruffoni, Alessandro; Julia, Fabio; Svejstrup, Thomas D.; McMillan, Alastair J.; Douglas, James J.; Leonori, Daniele published the artcile< Practical and regioselective amination of arenes using alkyl amines>, Recommanded Product: 5-Methoxyisoquinoline, the main research area is aromatic amine photoredox synthesis regioselective amination arene alkylamine.

The formation of carbon-nitrogen bonds for the preparation of aromatic amines is among the top five reactions carried out globally for the production of high-value materials, ranging from from bulk chems. to pharmaceuticals and polymers. As a result of this ubiquity and diversity, methods for their preparation impact the full spectrum of chem. syntheses in academia and industry. In general, these mols. are assembled through the stepwise introduction of a reactivity handle in place of an aromatic C-H bond (i.e., a nitro group, halogen or boronic acid) and a subsequent functionalization or cross-coupling. Here we show that aromatic amines can be constructed by direct reaction of arenes and alkyl amines using photocatalysis, without the need for pre-functionalization. The process enables the easy preparation of advanced building blocks, tolerates a broad range of functionalities, and multigram scale can be achieved via a batch-to-flow protocol. The merit of this strategy as a late-stage functionalization platform has been demonstrated by the modification of several drugs, agrochems., peptides, chiral catalysts, polymers and organometallic complexes.

Nature Chemistry published new progress about Amination, regioselective (photochem.). 90806-58-9 belongs to class isoquinoline, and the molecular formula is C10H9NO, Recommanded Product: 5-Methoxyisoquinoline.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Krapcho, A. Paul; Petry, Mary E.; Getahun, Zelleka; Landi, John J. Jr.; Stallman, John; Polsenberg, Johanna F.; Gallagher, Cynthia E.; Maresch, Martin J.; Hacker, Miles P. published the artcile< 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A Novel Class of Chromophore-Modified Antitumor Anthracene-9,10-diones: Synthesis and Antitumor Evaluations>, Recommanded Product: 6,9-Difluorobenzo[g]isoquinoline-5,10-dione, the main research area is anthracenedione preparation antitumor; benzoisoquinoline preparation antitumor.

Synthetic procedures have been developed which lead to the 2-aza congeners I (R = amine groups or N-containing heterocyclic groups) and several related N-oxides (II, R = NH2 or NMe2). I exhibited a wide range of in vitro cytotoxicity against L1210 leukemia, the human colon adenocarcinoma cell line LoVo, and the doxorubicin resistant LoVo/DX cell line. Selected analogs of I showed significant P388 antileukemic activity in mice with I (R = NH2, n = 2) exhibiting high activity. This activity was also retained in the related N-oxide II (R = NH2, n = 2). These heterocyclic bioisosteric models are representative of the first anthracene-9,10-diones which display antileukemic activity comparable to mitoxantrone.

Journal of Medicinal Chemistry published new progress about Antitumor agents. 144511-13-7 belongs to class isoquinoline, and the molecular formula is C13H5F2NO2, Recommanded Product: 6,9-Difluorobenzo[g]isoquinoline-5,10-dione.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Liang, Jun; Van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade S.; Chang, Christine; Delarosa, Donnie; De Voss, Jason; Driscoll, Jim; Eigenbrot, Charles; Goodacre, Simon; Ghilardi, Nico; MacLeod, Calum; Johnson, Adam; Bir Kohli, Pawan; Lai, Yingjie; Lin, Zhonghua; Mantik, Priscilla; Menghrajani, Kapil; Nguyen, Hieu; Peng, Ivan; Sambrone, Amy; Shia, Steven; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Williams, Karen; Wu, Lawren C.; Yang, Wenqian; Zhang, Birong; Magnuson, Steven published the artcile< Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model>, Computed Properties of 552331-06-3, the main research area is imidazopyridine derivative preparation TYK2 inhibitor psoriasis; IL-23; Imidazopyridine; Kinase; Psoriasis; TYK2.

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

Bioorganic & Medicinal Chemistry Letters published new progress about Antipsoriatic agents. 552331-06-3 belongs to class isoquinoline, and the molecular formula is C9H5BrClN, Computed Properties of 552331-06-3.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Evison, Benny J.; Palmer, James T.; Lambert, Gilles; Treutlein, Herbert; Zeng, Jun; Nativel, Brice; Chemello, Kevin; Zhu, Qing; Wang, Jie; Teng, Yanfen; Tang, Wei; Xu, Yanfeng; Rathi, Anuj Kumar; Kumar, Sanjay; Suchowerska, Alexandra K.; Parmar, Jasneet; Dixon, Ian; Kelly, Graham E.; Bonnar, James published the artcile< A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove>, Application In Synthesis of 721401-43-0, the main research area is cardiovascular disease PCSK9 LDL receptor cholesterol mall moleculep; Cardiovascular disease; LDL cholesterol; LDL receptor; Low density lipoprotein (LDL); Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9); Small molecule.

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low d. lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small mol. inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavorable for binding by small organic mols. Despite its challenging nature, we report herein the discovery of compound 3f as a small mol. inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chem., 3f emerged as a lead-like mol. by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered s.c. in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small mol. inhibitor against PCSK9 is therapeutically viable.

Bioorganic & Medicinal Chemistry published new progress about Bioavailability. 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Application In Synthesis of 721401-43-0.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Chilamari, Maheshwerreddy; Immel, Jacob R.; Bloom, Steven published the artcile< General Access to C-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media>, Safety of Isoquinolin-8-ylboronic acid, the main research area is radical preparation photocatalyzed oxidation boronic acid catalyst reaction mechanism; conjugate addition reaction radical Michael acceptor.

Carbon-centered radicals are indispensable building blocks for modern synthetic chem. In recent years, visible light photoredox catalysis has become a promising avenue to access C-centered radicals from a broad array of latent functional groups, including boronic acids. Herein, we present an aqueous protocol wherein water features a starring role to help transform aliphatic, aromatic, and heteroaromatic boronic acids to C-centered radicals with a bioinspired flavin photocatalyst. These radicals are used to deliver a diverse pool of alkylated products, including three pharmaceutically relevant compounds, via open-shell conjugate addition to disparate Michael acceptors. The mechanism of the reaction is investigated by computational studies, deuterium labeling, radical-trapping experiments, and spectroscopic anal.

ACS Catalysis published new progress about Alkylation (deborylative-alkylation). 721401-43-0 belongs to class isoquinoline, and the molecular formula is C9H8BNO2, Safety of Isoquinolin-8-ylboronic acid.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem